Gemcitabine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer, Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Pancreatic Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (1)
JP
  • Gemzar (Eli Lilly Japan): first approved March 1999; indicated for non-small cell lung cancer and pancreatic cancer (later additions: biliary tract, urothelial, breast, ovarian, lymphoma)
Product first approved 1999biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (245)
HR+/HER2- Metastatic Breast Cancer
NCT06343948 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-04-24 – 2027-12 · HR+HER2- Breast Cancer
What this study did
NCT00561119 · Samsung Medical Center
2007-05 – 2016-12 · Advanced Breast Cancer
What this study did
NCT02207335 · Tianjin Medical University Cancer Institute and Hospital
2013-12 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT02054338 · Pierre Fabre Medicament
2006-06 – 2015-02 · Advanced Breast Cancer
What this study did
NCT00236899 · Eli Lilly and Company
2005-09 – 2010-08 · Metastatic Breast Cancer (MBC)
What this study did
NCT00431106 · Hellenic Oncology Research Group
2002-04 – 2009-01 · Breast Cancer
What this study did
NCT00191152 · Eli Lilly and Company
2002-02 – 2008-11 · Breast Cancer, Breast Neoplasms, Cancer of the Breast
What this study did
NCT00440622 · Hellenic Oncology Research Group
2003-04 – 2008-11 · Breast Cancer
What this study did
NCT00191438 · Eli Lilly and Company
2002-10 – 2007-03 · Breast Neoplasms
What this study did
NCT00294385 · Central European Cooperative Oncology Group
2002-06 – 2005-10 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03164616 · AstraZeneca
2017-06-01 – 2027-11-15 · Non Small Cell Lung Cancer NSCLC
What this study did
NCT02486718 · Hoffmann-La Roche
2015-10-31 – 2026-08-26 · Non-Small Cell Lung Cancer
What this study did
NCT00324805 · National Cancer Institute (NCI)
2007-07-19 – 2025-01-31 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02998528 · Bristol-Myers Squibb
2017-03-04 – 2024-12-06 · Non Small Cell Lung Cancer
What this study did
NCT00981058 · Eli Lilly and Company
2010-01-07 – 2024-05-30 · Non Small Cell Lung Cancer
What this study did
NCT05493501 · EQRx International, Inc.
2022-12-14 – 2023-08-31 · NSCLC
What this study did
NCT03402048 · University of Turin, Italy
2012-07 – 2021-05 · Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms
What this study did
NCT01850303 · Intergroupe Francophone de Cancerologie Thoracique
2013-05-16 – 2020-01-31 · Non Small Cell Lung Cancer (Squamous or Non Squamous)
What this study did
NCT02579564 · Xinqiao Hospital of Chongqing
2016-10 – 2018-12 · Malignant Hydrothorax, Non Small Cell Lung Cancer
What this study did
NCT02859077 · Shanghai Pulmonary Hospital, Shanghai, China
2016-08 – 2018-07 · Non-Small-Cell Lung Cancer
What this study did
NCT03348904 · Incyte Corporation
2017-12-27 – 2018-05-22 · Lung Cancer
What this study did
NCT01631136 · Intergroupe Francophone de Cancerologie Thoracique
2012-07 – 2017-11-30 · Advanced Non Small Cell Lung Cancer
What this study did
NCT01404260 · Guangdong Association of Clinical Trials
2011-06 – 2015-10 · Non-small Cell Lung Cancer
What this study did
NCT00478699 · Spanish Lung Cancer Group
2007-06 – 2015-07 · Non-small-cell Lung Cancer
What this study did
NCT00617656 · Spanish Lung Cancer Group
2008-02 – 2015-04 · Non Small Cell Lung Cancer, BRCA1 Mutation
What this study did
NCT00907504 · Pfizer
2010-07 – 2014-05 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00003447 · Istituto Nazionale per lo Studio e la Cura dei Tumori
started 1998-07 · Lung Cancer
What this study did
NCT00006048 · AstraZeneca
started 2000-05 · Lung Cancer
What this study did
NCT00004100 · Istituto Nazionale per lo Studio e la Cura dei Tumori
started 1998-11 · Lung Cancer
What this study did
NCT00499109 · H. Lee Moffitt Cancer Center and Research Institute
2007-05 – 2013-11 · Non-Small Cell Lung Cancer
What this study did
NCT00540280 · King Faisal Specialist Hospital & Research Center
2003-10 – 2013-10 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00112710 · University Hospital Birmingham
started 2005-03 · Lung Cancer
What this study did
NCT00055887 · Spectrum Pharmaceuticals, Inc
started 2002-11 · Lung Cancer
What this study did
NCT00863512 · Alliance for Clinical Trials in Oncology
2009-03 – 2012-11 · Lung Cancer
What this study did
NCT00349219 · National Cancer Institute, Naples
2006-12 – 2012-06 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT00737867 · The Norwegian Lung Cancer Study Group
2007-09 – 2011-02 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT00198354 · Intergroupe Francophone de Cancerologie Thoracique
2001-05 – 2010-12 · Non-small Cell Lung Cancer Stage I and II, Peri-operative Chemotherapy
What this study did
NCT00329472 · Samsung Medical Center
2006-04 – 2010-07 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00442026 · Hellenic Oncology Research Group
2006-12 – 2010-05 · Non-small-cell Lung Cancer
What this study did
NCT00622349 · European Lung Cancer Working Party
2004-02 – 2009-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00079287 · Japan Multinational Trial Organization
2001-03 – 2008-11 · Lung Cancer
What this study did
NCT00254904 · Pfizer
2005-11 – 2008-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00345059 · National Cancer Institute, Naples
2005-05 – 2008-05 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT00074204 · Case Comprehensive Cancer Center
2003-10 – 2008-04 · Lung Cancer
What this study did
Phase 2/3 (39)
HR+/HER2- Metastatic Breast Cancer
NCT03423849 · Zhiyong Yu
2018-02-08 – 2020-02-08 · Breast Cancer, Chemotherapy Effect, Disease-free Survival
What this study did
Non-Small Cell Lung Cancer
NCT01631357 · Tianjin Medical University Cancer Institute and Hospital
2014-12 – 2018-12 · Non-small Cell Lung Cancer, Squamous Cell Carcinoma
What this study did
NCT01774578 · NewLink Genetics Corporation
2013-02 – 2016-06-18 · Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
What this study did
NCT00022009 · The Christie NHS Foundation Trust
started 2001-07 · Lung Cancer
What this study did
NCT00385606 · National Cancer Institute, Naples
2003-01 – 2006-07 · Advanced Non-small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT06783140 · University Health Network, Toronto
2025-06-10 – 2031-06-02 · Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation
What this study did
NCT03721744 · 1Globe Health Institute LLC
2018-10-25 – 2025-09 · Metastatic Pancreatic Cancer
What this study did
NCT03512756 · Tyme, Inc
2018-03-27 – 2021-12-28 · Pancreatic Cancer
What this study did
NCT01598584 · Tianjin Medical University Cancer Institute and Hospital
2012-06 – 2015-12 · Pancreatic Cancer
What this study did
NCT01065870 · Columbia University
2009-12 – 2014-12 · Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
What this study did
NCT00192712 · Rambam Health Care Campus
2002-11 – 2010-09 · Pancreatic Cancer
What this study did
NCT00960284 · IRCCS San Raffaele
2003-06 – 2009-06 · Pancreatic Cancer
What this study did
NCT00064207 · European Organisation for Research and Treatment of Cancer - EORTC
2003-05 – 2007-01 · Pancreatic Cancer
What this study did
NCT00113256 · Astex Pharmaceuticals, Inc.
2005-02 – 2006-02 · Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06115499 · Alliance for Clinical Trials in Oncology
2024-08-13 – 2028-01-01 · Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03251365 · Hospital General de Ciudad Real
2017-07-27 – 2024-12-31 · Resectable Pancreatic Adenocarcinoma
What this study did
NCT03673137 · Fuda Cancer Hospital, Guangzhou
2019-09-01 – 2021-07-30 · Locally Advanced Pancreatic Adenocarcinoma
What this study did
Other / comorbidity
NCT02135042 · NRG Oncology
2014-07-01 – 2034-01-01 · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
What this study did
NCT04559139 · ECOG-ACRIN Cancer Research Group
2021-02-24 – 2029-06-30 · Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
What this study did
NCT06037980 · Gruppo Oncologico del Nord-Ovest
2023-11-07 – 2029-01 · Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT06923475 · Amsterdam UMC, location VUmc
2026-04-17 – 2028-11-06 · Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable, Borderline Resectable
What this study did
NCT07198451 · Shanghai University of Traditional Chinese Medicine
2025-10 – 2028-06 · Non Muscle Invasive Bladder Cancer
What this study did
NCT02641847 · Fudan University
2016-01 – 2027-12 · Triple Negative Breast Cancer, Breast Cancer
What this study did
NCT02867865 · Tata Memorial Hospital
2016-09-06 – 2027-09-10 · Gall Bladder Cancers
What this study did
NCT06268327 · Assiut University
2024-04-30 – 2026-10-30 · Breast Cancer
What this study did
NCT03366272 · Universität des Saarlandes
2017-12-05 – 2025-01-15 · Lymphoma, Non-Hodgkin
What this study did
NCT05576272 · Qilu Pharmaceutical Co., Ltd.
2022-05-19 – 2024-12-30 · Nasopharyngeal Carcinoma
What this study did
NCT05487443 · First People's Hospital of Hangzhou
2022-08-01 – 2024-08-30 · Gemcitabine, Biliary Tract Cancer, Immune Checkpoint Inhibitors
What this study did
NCT00997906 · National Cancer Centre, Singapore
2009-09-15 – 2023-12-31 · Head and Neck Cancer
What this study did
NCT03674242 · ERYtech Pharma
2019-06-13 – 2022-03-31 · Triple Negative Breast Cancer
What this study did
NCT02807181 · Sirtex Medical
2017-02-14 – 2021-04-29 · Intrahepatic Cholangiocarcinoma
What this study did
NCT02240017 · Institut Claudius Regaud
2015-01-21 – 2019-07-15 · Advanced Urothelial Cancer, Metastatic Urothelial Cancer
What this study did
NCT02527772 · Guangxi Medical University
2015-09 – 2018-09 · Hepatocellular Carcinoma
What this study did
NCT02534337 · Guangxi Medical University
2015-09 – 2017-09 · Hepatocellular Carcinoma
What this study did
NCT01881230 · Celgene
2013-09-26 – 2016-10-28 · Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02099396 · China Association of Osteosarcoma Chemotherapy
2014-04 – 2016-06 · Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
What this study did
NCT00304135 · Federation Francophone de Cancerologie Digestive
2005-10 – 2012-12 · Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
What this study did
NCT00014274 · European Organisation for Research and Treatment of Cancer - EORTC
2001-01 – 2008-03 · Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
What this study did
Phase 2 (1124)
HR+/HER2- Metastatic Breast Cancer
NCT06531447 · The National Center of Oncology, Azerbaijan
2014-05 – 2027-05 · Breast Cancer
What this study did
NCT03678883 · Actuate Therapeutics Inc.
2019-01-04 – 2026-06 · Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
What this study did
NCT06630325 · OHSU Knight Cancer Institute
2025-06-24 – 2026-03-11 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
What this study did
NCT04739670 · Peter MacCallum Cancer Centre, Australia
2021-03-01 – 2025-09-30 · Metastatic Triple Negative Breast Cancer
What this study did
NCT04659603 · Sanofi
2021-03-29 – 2025-01-19 · Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
What this study did
NCT04143906 · Shandong Cancer Hospital and Institute
2019-10-25 – 2024-12-31 · Metastatic Breast Cancer
What this study did
NCT05263882 · Fifth Affiliated Hospital, Sun Yat-Sen University
2022-03 – 2024-09 · HER2-negative Breast Cancer
What this study did
NCT03025880 · Spanish Breast Cancer Research Group
2017-06-28 – 2021-07-22 · Advanced Breast Cancer
What this study did
NCT02263495 · Asan Medical Center
2014-12-19 – 2019-06-17 · Metastatic Breast Cancer
What this study did
NCT02489409 · Xinjiang Medical University
2015-10 – 2018-07 · Breast Neoplasms
What this study did
NCT02544243 · Shandong Cancer Hospital and Institute
2015-09 – 2017-08 · Metastatic Breast Cancer
What this study did
NCT01550848 · Fudan University
2012-01 – 2015-06 · Metastatic Breast Cancer
What this study did
NCT01352494 · Korean Breast Cancer Study Group
2011-05 – 2015-05 · Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT00618826 · Barbara Ann Karmanos Cancer Institute
2006-11 – 2014-02 · Metastatic Breast Cancer
What this study did
NCT00462865 · Brown University
2007-11 – 2014-01 · Breast Cancer
What this study did
NCT00027989 · Pharmatech Oncology
started 2001-12 · Breast Cancer
What this study did
NCT00662129 · Alliance for Clinical Trials in Oncology
2008-11 – 2013-08 · Breast Cancer
What this study did
NCT00212069 · National University Hospital, Singapore
2004-03 – 2013-04 · Metastatic Breast Cancer
What this study did
NCT00403130 · George Albert Fisher
2006-02 – 2012-11 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00493636 · Accelerated Community Oncology Research Network
2007-06 – 2012-11 · Breast Cancer
What this study did
NCT00695994 · National University Hospital, Singapore
2006-10 – 2012-09 · Non Small Cell Lung Cancer, Breast Cancer
What this study did
NCT00320541 · Eli Lilly and Company
2006-05 – 2012-08 · Breast Cancer
What this study did
NCT00754351 · University Hospital of Crete
2008-09 – 2012-02 · Breast Cancer
What this study did
NCT00532857 · Jungsil Ro
2007-03 – 2011-09 · Breast Cancer
What this study did
NCT01050322 · Latin American Cooperative Oncology Group
2009-11 – 2011-09 · BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy, Patient With Progression After Taxanes
What this study did
NCT00503906 · University of Miami
2007-06 – 2011-03 · Breast Cancer
What this study did
NCT00623233 · Eli Lilly and Company
2008-03 – 2011-01 · Metastatic Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT00480597 · Ludwig-Maximilians - University of Munich
started 2002-10 · Metastatic Breast Cancer
What this study did
NCT00110084 · Mayo Clinic
2005-08 – 2010-08 · Breast Cancer
What this study did
NCT00191269 · Eli Lilly and Company
2005-06 – 2010-03 · Metastatic Breast Cancer
What this study did
NCT00334802 · Eli Lilly and Company
2006-06 – 2010-03 · Metastatic Breast Cancer
What this study did
NCT00191854 · Eli Lilly and Company
2005-03 – 2009-11 · Breast Cancer
What this study did
NCT00201760 · Kari Kendra
2005-02-25 – 2009-10-31 · Breast Cancer
What this study did
NCT00244933 · Barbara Ann Karmanos Cancer Institute
2004-02 – 2009-10 · Breast Cancer
What this study did
NCT00193063 · SCRI Development Innovations, LLC
2001-07 – 2009-08 · Breast Cancer
What this study did
NCT00193206 · SCRI Development Innovations, LLC
2005-09 – 2009-05 · Breast Cancer
What this study did
NCT00191243 · Eli Lilly and Company
2002-03 – 2009-04 · Breast Cancer
What this study did
NCT00193050 · SCRI Development Innovations, LLC
2001-11 – 2009-03 · Breast Cancer
What this study did
NCT00059852 · Alliance for Clinical Trials in Oncology
2003-06 – 2009-01 · Breast Cancer
What this study did
NCT00470249 · University of Southampton
2006-07-15 – 2008-11-03 · Breast Cancer
What this study did
NCT00193076 · SCRI Development Innovations, LLC
2003-11 – 2008-10 · Breast Cancer
What this study did
NCT00006007 · Alliance for Clinical Trials in Oncology
2000-12 – 2008-05 · Breast Cancer
What this study did
NCT00316199 · Eli Lilly and Company
2006-04 – 2008-04 · Metastatic Breast Cancer
What this study did
NCT00063570 · Eli Lilly and Company
2003-07 – 2008-01 · Breast Cancer, Breast Neoplasms
What this study did
NCT00191815 · Eli Lilly and Company
2002-10 – 2007-10 · Breast Cancer
What this study did
NCT00192062 · Eli Lilly and Company
2004-07 – 2007-06 · Breast Cancer
What this study did
NCT00159458 · University of Southern California
2003-07 – 2006-12 · Recurrent Breast Cancer, Metastastic Breast Cancer
What this study did
NCT00191672 · Eli Lilly and Company
2003-12 – 2006-11 · Breast Neoplasms
What this study did
Phase 1/2 (257)
HR+/HER2- Metastatic Breast Cancer
NCT02393248 · Incyte Corporation
2015-02-27 – 2021-12-17 · Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
What this study did
NCT02331251 · Western Regional Medical Center
2014-12 – 2018-01 · Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
What this study did
NCT01070706 · Jungsil Ro
2009-03 – 2010-11 · Breast Cancer
What this study did
NCT00100750 · National Cancer Institute (NCI)
2005-09 – 2010-01 · Recurrent Breast Carcinoma, Stage IV Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06694454 · National Cancer Institute (NCI)
2026-11-24 – 2034-12-31 · Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
What this study did
NCT04216316 · National Cancer Institute (NCI)
2021-04-14 – 2027-03-18 · Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT02422381 · Providence Health & Services
2015-07-20 – 2026-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05616624 · Washington University School of Medicine
2023-04-05 – 2026-07-22 · Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
What this study did
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04731467 · Famewave Ltd.
2021-03-19 – 2024-09-30 · Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
What this study did
NCT04068896 · NGM Biopharmaceuticals, Inc
2019-10-16 – 2024-01-08 · Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
What this study did
NCT03317496 · Pfizer
2017-12-21 – 2022-12-20 · Non-small Cell Lung Cancer, Urothelial Cancer
What this study did
NCT03840915 · EMD Serono Research & Development Institute, Inc.
2019-04-02 – 2022-07-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02651441 · Shenzhen Hornetcorn Bio-technology Company, LTD
2016-02 – 2019-08 · Lung Cancer, Non-small Cell Lung Cancer
What this study did
NCT01763788 · Eli Lilly and Company
2013-05-07 – 2018-10-17 · Squamous Non-small Cell Lung Cancer
What this study did
NCT02175381 · Hellenic Oncology Research Group
2011-02 – 2014-04 · NSCLC
What this study did
NCT00743379 · Threshold Pharmaceuticals
2008-08 – 2014-03 · Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
What this study did
NCT00138658 · Achieve Life Sciences
2004-11 – 2010-03 · Non-small Cell Lung Cancer
What this study did
NCT00071136 · Eli Lilly and Company
2003-12 – 2006-08 · Lung Neoplasms
What this study did
NCT00003202 · Wake Forest University Health Sciences
1998-01 – 2006-07 · Lung Cancer
What this study did
NCT01004731 · University of Alabama at Birmingham
2001-06 – 2006-01 · Stage IV Non-Small Cell Lung Cancer
What this study did
NCT00062270 · University of Alabama at Birmingham
2003-05 – 2004-09 · Lung Cancer
What this study did
NCT00004160 · University of Alabama at Birmingham
2000-02 – 2004-05 · Lung Cancer
What this study did
NCT00003037 · Memorial Sloan Kettering Cancer Center
1997-04 – 2002-03 · Lung Cancer
What this study did
NCT00004093 · Northwestern University
1999-08 – 2002-03 · Lung Cancer
What this study did
NCT00004159 · University of Alabama at Birmingham
2000-02 – 2000-02 · Lung Cancer
What this study did
Ovarian Cancer
NCT06055348 · Biocity Biopharmaceutics Co., Ltd.
2023-10-30 – 2025-11-30 · Serous Ovarian Cancer, Advanced Ovarian Cancer
What this study did
NCT03314935 · Incyte Corporation
2017-11-21 – 2022-11-28 · Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors
What this study did
NCT00910000 · Dana-Farber Cancer Institute
2009-06 – 2015-10 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT01624493 · Hoosier Cancer Research Network
2012-10 – 2014-10 · Ovarian Cancer
What this study did
NCT00551122 · University of Southampton
2006-11 – 2013-04 · Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
What this study did
NCT00429559 · Hellenic Oncology Research Group
2006-06 – 2011-07 · Ovarian Cancer
What this study did
Pancreatic Cancer
NCT07945782 · Tianjin Medical University Cancer Institute and Hospital
2026-12-01 – 2030-02-20 · Locally Advanced Pancreatic Cancer, Immunotherapy Combined With Chemotherapy
What this study did
NCT05669482 · Verastem, Inc.
2023-03-22 – 2027-08-31 · KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
What this study did
NCT06370754 · Fudan University
2024-04-30 – 2027-04-30 · Pancreatic Cancer
What this study did
NCT05827796 · InxMed (Shanghai) Co., Ltd.
2022-12-08 – 2026-12-31 · Pancreatic Cancer
What this study did
NCT05141149 · Prestige Biopharma Limited
2023-06-05 – 2026-12 · Pancreatic Cancer
What this study did
NCT03417921 · Ability Pharmaceuticals SL
2021-04-26 – 2025-12-31 · Pancreatic Cancer
What this study did
NCT02705196 · Lokon Pharma AB
2016-11 – 2025-11-15 · Pancreatic Cancer
What this study did
NCT05064618 · Nagoya University
2021-08-23 – 2025-11-01 · Pancreatic Cancer
What this study did
NCT05832892 · Shanghai Zhongshan Hospital
2023-11-01 – 2025-06-01 · Unresectable Locally Advanced or Metastatic Pancreatic Cancer
What this study did
NCT02632448 · Esperas Pharma Inc.
2016-05-16 – 2025-04-14 · Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
What this study did
NCT05304936 · ImmunityBio, Inc.
2022-10-17 – 2025-02-15 · Advanced Pancreatic Carcinoma
What this study did
NCT03997968 · Cyteir Therapeutics, Inc.
2019-10-09 – 2024-12-20 · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
What this study did
NCT02481635 · University Health Network, Toronto
2016-12-08 – 2024-12-10 · Pancreatic Cancer
What this study did
NCT04247165 · Herlev Hospital
2020-06-02 – 2024-12-05 · Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
What this study did
NCT05580445 · Shouyao Holdings (Beijing) Co. LTD
2022-08-11 – 2024-08-11 · Advanced Pancreatic Cancer
What this study did
NCT04683939 · BioNTech SE
2022-01-18 – 2023-07-24 · Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
What this study did
NCT03184870 · Bristol-Myers Squibb
2017-08-08 – 2023-06-14 · Colorectal Cancer, Pancreatic Cancer
What this study did
Phase 1 (450)
HR+/HER2- Metastatic Breast Cancer
NCT04796220 · Patrick Dillon, MD
2022-01-27 – 2030-02 · Breast Cancer, Breast Neoplasms
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT02009449 · Eli Lilly and Company
2013-11-15 – 2023-07-22 · Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
What this study did
NCT04247126 · Syros Pharmaceuticals
2020-01-23 – 2023-03-30 · Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
What this study did
NCT03432741 · Mayo Clinic
2018-03-27 – 2022-10-03 · Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02479230 · Joseph Baar, MD, PhD
2015-07-17 – 2022-07-01 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02784795 · Eli Lilly and Company
2016-11-04 – 2020-02-13 · Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
What this study did
NCT01803282 · Gilead Sciences
2013-03-29 – 2019-04-23 · Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
What this study did
NCT02046421 · University of Chicago
2013-11 – 2018-05 · Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01929941 · Incyte Corporation
2013-09 – 2014-08 · Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
What this study did
NCT00270907 · M.D. Anderson Cancer Center
2005-12 – 2012-10 · Metastatic Breast Cancer, Breast Cancer
What this study did
NCT01133912 · Jungsil Ro
2009-03 – 2011-10 · Breast Cancer
What this study did
NCT00049608 · National Center for Complementary and Integrative Health (NCCIH)
2002-07 – 2011-08 · Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
What this study did
NCT00620295 · Masonic Cancer Center, University of Minnesota
2007-03 – 2009-10 · Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
What this study did
NCT00004095 · Northwestern University
1999-08 – 2008-10 · Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
What this study did
NCT00014456 · Dartmouth-Hitchcock Medical Center
2000-03 – 2005-10 · Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
What this study did
Non-Small Cell Lung Cancer
NCT02889666 · Shanghai Jiao Tong University School of Medicine
2008-01 – 2027-12 · Recurrent Non-small Cell Lung Cancer
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT03421353 · AstraZeneca
2018-02-07 – 2024-03-28 · Advanced Solid Tumours
What this study did
NCT02857270 · Eli Lilly and Company
2016-09-29 – 2022-10-24 · Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT03064854 · Novartis Pharmaceuticals
2017-05-24 – 2021-07-28 · Non-small Cell Lung Cancer
What this study did
NCT03920839 · Incyte Corporation
2019-07-15 – 2019-11-04 · Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
What this study did
NCT02079636 · Eli Lilly and Company
2014-03-28 – 2019-08-29 · Carcinoma, Non-small Cell Lung
What this study did
NCT02537561 · Washington University School of Medicine
2015-12 – 2018-12 · Solid Tumors, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
What this study did
NCT01346540 · Boehringer Ingelheim
2011-04-14 – 2017-01-17 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01971489 · Roswell Park Cancer Institute
2015-09 – 2016-08 · Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT01809210 · AstraZeneca
2013-04-04 – 2016-01-04 · Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
What this study did
NCT02728492 · NewVac LLC
2013-08 – 2016-01 · Non-small Cell Lung Cancer, Epithelial Ovarian Cancer
What this study did
NCT02083679 · EMD Serono
2014-07 – 2015-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01714037 · Debiopharm International SA
2012-08 – 2014-11 · Non-small Cell Lung Cancer
What this study did
NCT01641575 · Clovis Oncology, Inc.
2012-07 – 2013-06 · Solid Tumor, Non-small-cell Lung Cancer, Lung Cancer
What this study did
NCT01282333 · National Cancer Institute (NCI)
2011-01 – 2013-02 · Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
What this study did
NCT01466647 · Axelar AB
2011-01 – 2012-09 · Non Small Cell Lung Cancer
What this study did
NCT00678977 · GlaxoSmithKline
2008-04-03 – 2011-06-30 · Lung Cancer, Non-Small Cell
What this study did
NCT00016315 · Radiation Therapy Oncology Group
2001-05 – 2010-06 · Lung Cancer
What this study did
NCT00423449 · Merck Sharp & Dohme LLC
2007-03 – 2010-04 · Non-Small Cell Lung Cancer
What this study did
NCT00560573 · Pfizer
2007-11 – 2010-03 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00619021 · Masonic Cancer Center, University of Minnesota
2003-01 – 2009-01 · Lung Cancer
What this study did
NCT00343408 · NCIC Clinical Trials Group
2005-11-29 – 2008-09-22 · Colorectal Cancer, Lung Cancer
What this study did
NCT00066768 · National Cancer Institute (NCI)
2003-07 – 2008-03 · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT00496275 · Genzyme, a Sanofi Company
2006-08 – 2007-05 · Non Small Cell Lung Cancer
What this study did
NCT00052338 · National Cancer Institute (NCI)
2002-09 – 2004-05 · Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT02627443 · National Cancer Institute (NCI)
2017-05-16 – 2027-06-03 · Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
What this study did
NCT03872947 · Toray Industries, Inc
2019-04-26 – 2026-07-16 · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT01279291 · Kyowa Kirin Co., Ltd.
2011-01 – 2012-11 · Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
What this study did
NCT00410553 · National Cancer Institute (NCI)
2006-11-14 – 2012-10-24 · Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7
What this study did
NCT00004082 · Beth Israel Deaconess Medical Center
1999-07 – 2010-12 · Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
What this study did
Phase 4 (19)
Non-Small Cell Lung Cancer
NCT04331626 · Henan Cancer Hospital
2020-04 – 2023-04 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT02299765 · Sichuan University
2014-12 – 2017-10 · Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation
What this study did
NCT02316327 · Fundacion Clinic per a la Recerca Biomédica
2013-07 – 2016-10 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT01336192 · Tongji University
2011-04 – 2013-04 · Non Small Cell Lung Cancer
What this study did
NCT01028729 · Simcere Pharmaceutical Co., Ltd
2009-09 – 2011-08 · Non-small Cell Lung Cancer (NSCLC)
What this study did
Pancreatic Cancer
NCT05035147 · Tianjin Medical University Cancer Institute and Hospital
2021-03-25 – 2026-12 · Pancreatic Cancer
What this study did
NCT02812992 · AIO-Studien-gGmbH
2016-06 – 2021-02 · Adenocarcinoma Pancreas
What this study did
Pancreatic Ductal Adenocarcinoma
NCT04480268 · IRCCS San Raffaele
2020-07-08 – 2026-01-01 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT03401827 · Seoul National University Hospital
2018-03-01 – 2019-01-01 · Pancreatic Adenocarcinoma, Chemotherapy Effect
What this study did
Other / comorbidity
NCT06820255 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2025-01-07 – 2027-01-07 · Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
What this study did
NCT05723991 · Chunguang yang (101937)
2022-09-28 – 2025-09-28 · Radical Cystectomy, Urothelial Carcinoma
What this study did
NCT05701332 · Assiut University
2023-04-01 – 2025-01-18 · Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis, Non Muscle Invasive Bladder Cancer
What this study did
NCT04999878 · Zhengzhou University
2021-05-30 – 2024-06-30 · Hemophagocytic Syndrome, T/NK-Cell Lymphoma
What this study did
NCT04040491 · Mingzhi Zhang
2019-09-01 – 2021-09-01 · Peripheral T-cell Lymphoma
What this study did
NCT01501136 · Mingzhi Zhang
2011-01 – 2019-05 · Nasal and Nasal-type NK/T-cell Lymphoma
What this study did
NCT01501149 · Mingzhi Zhang
2011-01 – 2019-05 · Nasal and Nasal-type NK/T-cell Lymphoma
What this study did
NCT00352859 · Bayer
2006-08 – 2006-11 · Carcinoma, Renal Cell
What this study did
Early phase / not applicable (51)
Non-Small Cell Lung Cancer
NCT02194738 · National Cancer Institute (NCI)
2014-09-26 – 2027-09-21 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT06576635 · University of Illinois at Chicago
2024-12-16 – 2026-09 · NSCLC
What this study did
NCT02145078 · Barbara Ann Karmanos Cancer Institute
2014-06 – 2017-03-07 · Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT01201044 · Third Military Medical University
2010-01 – 2012-12 · Non-small Cell Lung Cancer
What this study did
NCT00883480 · Spanish Lung Cancer Group
2005-06 – 2008-11 · Non-small Cell Lung Cancer
What this study did
NCT00283478 · Kentuckiana Cancer Institute
2004-05 – 2007-04 · Non-Small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT07928362 · Ruijin Hospital
2026-10-28 – 2029-08-30 · Pancreatic Neoplasms, Neoplasm Metastasis
What this study did
NCT06494514 · Du Juan
2024-04-01 – 2027-04-01 · Locally Advanced Pancreatic Cancer
What this study did
NCT05903703 · Zhang Xiaofeng,MD
2023-10-01 – 2027-03-31 · Pancreatic Cancer
What this study did
NCT04181645 · RenJi Hospital
2019-06-29 – 2023-05-01 · Pancreatic Cancer Stage IV
What this study did
NCT02318095 · Duke University
2015-02-17 – 2022-11-14 · Resectable Pancreatic Cancers
What this study did
NCT03076216 · OncoSil Medical Limited
2017-08-01 – 2020-11-28 · Unresectable Locally Advanced Pancreatic Carcinoma
What this study did
NCT02981719 · Fuda Cancer Hospital, Guangzhou
2016-10-01 – 2020-10-01 · Pancreatic Cancer
What this study did
NCT03003078 · OncoSil Medical Limited
2017-03-27 – 2020-07-31 · Unresectable Locally Advanced Pancreatic Carcinoma
What this study did
NCT01938716 · M.D. Anderson Cancer Center
2012-03 – 2019-06-03 · Pancreatic Cancer
What this study did
NCT01683422 · Loma Linda University
2013-01-02 – 2019-02-19 · Pancreatic Cancer
What this study did
NCT01989000 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2013-11 – 2017-12 · Pancreatic Cancer
What this study did
NCT02486497 · Seoul National University Hospital
2015-06 – 2017-05 · Pancreatic Cancer
What this study did
NCT02245217 · University of Utah
2014-12-12 – 2016-03-17 · Pancreatic Cancer
What this study did
NCT01442974 · Grupo Hospital de Madrid
2011-01 – 2012-06 · Pancreatic Cancer
What this study did
NCT00448838 · University of Miami
2006-05 – 2011-03 · Pancreatic Cancer
What this study did
NCT00524069 · Roswell Park Cancer Institute
2007-01 – 2007-11 · Pancreatic Cancer
What this study did
NCT00159471 · University of Southern California
2005-02 – 2006-07 · Pancreatic Cancer
What this study did
NCT00003851 · Columbia University
1999-03 – 2004-07 · Malnutrition, Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06046794 · Institut Paoli-Calmettes
2024-05-23 – 2029-11 · Cancer Of Pancreas
What this study did
NCT02496832 · University Health Network, Toronto
2014-11 – 2014-11 · Pancreatic Adenocarcinoma, Advanced Disease, Metastatic Disease
What this study did
Other / comorbidity
NCT06167057 · Carmel Medical Center
2023-04-17 – 2028-01-30 · UTUC
What this study did
NCT05717790 · Fourth Affiliated Hospital of Guangxi Medical University
2022-12-01 – 2027-11-30 · Nasopharyngeal Carcinoma by AJCC V8 Stage
What this study did
NCT06313554 · Fudan University
2024-05-20 – 2027-05-20 · Intrahepatic Cholangiocarcinoma
What this study did
NCT06162468 · University of Auckland, New Zealand
2025-05-31 – 2026-07-31 · Intraductal Papillary Mucinous Neoplasm of Pancreas
What this study did
NCT06349044 · Zhejiang Cancer Hospital
2024-03-20 – 2025-12-31 · Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma
What this study did
NCT07062484 · Sichuan Cancer Hospital and Research Institute
2025-07 – 2025-12 · Lung Metastatic Nasopharyngeal Carcinoma
What this study did
NCT05821192 · Ou Bai, MD/PHD
2023-03-23 – 2024-12-31 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma
What this study did
NCT01495676 · Institut du Cancer de Montpellier - Val d'Aurelle
2011-07-06 – 2024-12-07 · Infiltrating Bladder Urothelial Carcinoma
What this study did
NCT05671900 · Clinical Hospital Centre Zagreb
2020-04-01 – 2024-12 · Non-muscle-invasive Bladder Cancer
What this study did
NCT05626101 · Al-Azhar University
2021-01-01 – 2024-10-11 · Non-muscle-invasive Bladder Cancer
What this study did
NCT05431244 · Samsung Medical Center
2022-07-01 – 2024-07-01 · Gastric Cancer
What this study did
NCT03789864 · Indiana University
2019-10-07 – 2024-05-01 · Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
What this study did
NCT02512692 · Medical University of South Carolina
2015-07-21 – 2021-03-19 · Intrahepatic Cholangiocarcinoma
What this study did
NCT02716961 · The First Affiliated Hospital with Nanjing Medical University
2016-01 – 2020-12 · Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence, Prognosis
What this study did
NCT02778308 · Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
2012-01 – 2018-12 · Gallbladder Cancer
What this study did
NCT01343121 · The Christie NHS Foundation Trust
2012-02-02 – 2017-11-24 · Bladder Cancer
What this study did
NCT02944357 · Mayo Clinic
2016-11 – 2017-09-05 · Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
What this study did
NCT01958580 · Albert Einstein College of Medicine
2013-09-17 – 2017-02-24 · Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
What this study did
NCT02256982 · Massachusetts General Hospital
2014-10 – 2016-03 · Unresectable Intrahepatic Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma
What this study did
NCT01411072 · AHS Cancer Control Alberta
2011-09 – 2015-12 · Pancreas Cancer
What this study did
NCT01801644 · Barmherzige Brüder Vienna
2007-04 – 2013-02 · Bladder Cancer
What this study did
NCT00614835 · Memorial Sloan Kettering Cancer Center
2001-08 – 2012-01 · Uterine Leiomyosarcoma, Uterine Cancer
What this study did
NCT01125020 · Shanghai Jiao Tong University School of Medicine
2008-12 – 2010-12 · Liver Transplantation, Hepatocellular Carcinoma, Tumor Recurrence and Metastasis, Survival, Adjuvant Chemotherapy
What this study did
Used as active comparator (245)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (146)
HR+/HER2- Metastatic Breast Cancer
NCT06255392 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
What this study did
NCT07406542 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-04-01 – 2030-04-01 · Recurrent or Metastatic Breast Cancer
What this study did
NCT06079983 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2023-12-01 – 2029-03-01 · Breast Cancer
What this study did
NCT06383767 · Qilu Pharmaceutical Co., Ltd.
2024-07-11 – 2028-07-31 · Metastatic Breast Cancer
What this study did
NCT05814354 · Jiangsu HengRui Medicine Co., Ltd.
2023-06-30 – 2028-06-30 · Breast Cancer
What this study did
NCT06143553 · Shanghai Yizhong Pharmaceutical Co., Ltd.
2023-09-25 – 2028-06-30 · Metastatic Breast Cancer (MBC)
What this study did
NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-17 – 2028-06-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06268652 · Sun Yat-sen University
2024-01-15 – 2028-01-15 · Breast Cancer, Refractory Breast Carcinoma
What this study did
NCT06081959 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023-10-31 – 2027-12-31 · Metastatic Breast Cancer
What this study did
NCT06957886 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-05-15 – 2027-12 · HER2-low Breast Cancer
What this study did
NCT04639986 · Gilead Sciences
2020-11-23 – 2026-12 · Metastatic Breast Cancer
What this study did
NCT01646034 · The Netherlands Cancer Institute
2014-09 – 2026-10 · Breast Cancer
What this study did
NCT03901339 · Gilead Sciences
2019-05-08 – 2023-10-20 · Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03456076 · Hoffmann-La Roche
2018-08-16 – 2031-11-19 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
NCT06908304 · Maia Biotechnology
2025-12-08 – 2027-12-31 · Carcinoma, Non-Small -Cell Lung
What this study did
NCT02453282 · AstraZeneca
2015-07-21 – 2026-12-31 · Non-Small-Cell Lung Carcinoma NSCLC
What this study did
NCT02542293 · AstraZeneca
2015-11-03 – 2026-12-31 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT03003962 · AstraZeneca
2017-01-02 – 2026-06-30 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT03088540 · Regeneron Pharmaceuticals
2017-05-29 – 2025-04-18 · Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
What this study did
NCT04222972 · Hoffmann-La Roche
2020-07-24 – 2025-01-27 · RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue
What this study did
NCT01656551 · National Cancer Institute, Naples
2012-08 – 2024-11 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT02576574 · EMD Serono Research & Development Institute, Inc.
2015-10-29 – 2024-01-29 · First Line Non-Small Cell Lung Cancer
What this study did
NCT02041533 · Bristol-Myers Squibb
2014-03-27 – 2022-05-27 · Stage IV or Recurrent Non-Small Cell Lung Cancer
What this study did
NCT02409342 · Hoffmann-La Roche
2015-07-20 – 2022-03-08 · Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
What this study did
NCT02142738 · Merck Sharp & Dohme LLC
2014-08-25 – 2021-05-27 · Non-Small Cell Lung Carcinoma
What this study did
NCT01121393 · Boehringer Ingelheim
2010-04-19 – 2017-11-26 · Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
What this study did
NCT00446225 · Spanish Lung Cancer Group
2007-02-15 – 2012-12 · Non-Small Cell Lung Cancer
What this study did
NCT01005680 · Eli Lilly and Company
2009-11 – 2012-11 · Non Small Cell Lung Cancer
What this study did
NCT00298415 · Intergroupe Francophone de Cancerologie Thoracique
2006-03 – 2011-12 · NSCLC
What this study did
NCT00300586 · Hospices Civils de Lyon
2006-06 – 2011-03 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT00087711 · Eli Lilly and Company
2004-07 – 2008-03 · Non Small Cell Lung Carcinoma
What this study did
Ovarian Cancer
NCT07821606 · Hansoh BioMedical R&D Company
2026-11-01 – 2031-12-30 · Platinum-sensitive Recurrent Ovarian Cancer
What this study did
NCT07213804 · Eli Lilly and Company
2025-10-22 – 2031-08 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
What this study did
NCT07286266 · GlaxoSmithKline
2026-06-18 – 2030-07-22 · Ovarian Neoplasms
What this study did
NCT07604766 · Genmab
2026-06-26 – 2028-12 · Platinum-resistant Ovarian Cancer
What this study did
NCT06828354 · Jiangsu HengRui Medicine Co., Ltd.
2025-03-13 – 2027-12 · Ovarian Cancer
What this study did
Phase 2/3 (19)
Non-Small Cell Lung Cancer
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT01407822 · Guangdong Association of Clinical Trials
2011-12-05 – 2022-12 · Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT05870748 · Sutro Biopharma, Inc.
2023-07-12 – 2025-08-26 · Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
What this study did
Pancreatic Cancer
NCT04037241 · Sorrento Therapeutics, Inc.
2021-11-01 – 2022-01-01 · Malignant Tumor of Pancreas Metastatic to Liver
What this study did
NCT00112658 · UNICANCER
2004-11 – 2010-06-30 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT06493552 · Vasgene Therapeutics, Inc
2025-03-15 – 2034-08 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
What this study did
NCT07106762 · Bristol-Myers Squibb
2025-09-30 – 2033-11-18 · Urothelial Cancer
What this study did
NCT06879145 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2031-12 · Muscular Invasive Bladder Cancer (MIBC)
What this study did
NCT07608224 · West China Hospital
2026-06-20 – 2030-12-31 · Urinary Bladder Neoplasms
What this study did
NCT04890522 · Sun Yat-sen University
2021-07-01 – 2028-12-31 · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy, Survival
What this study did
NCT03086993 · Delcath Systems Inc.
2018-04-10 – 2023-05 · Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
What this study did
NCT03610100 · The Clatterbridge Cancer Centre NHS Foundation Trust
2015-12 – 2022-12 · Pancreatic Acinar Carcinoma, Pancreatic Neoplasms
What this study did
NCT02172976 · Krankenhaus Nordwest
2014-11 – 2020-05 · Resectable Prancreas Carcinoma
What this study did
NCT02777788 · Shanghai University of Traditional Chinese Medicine
2014-09 – 2019-12 · Cancer
What this study did
NCT01197560 · Celgene
2010-09-02 – 2018-04-05 · Diffuse Large B-cell Lymphoma
What this study did
NCT02213744 · Merrimack Pharmaceuticals
2014-07 – 2017-06 · Breast Cancer, HER2 Positive Breast Cancer
What this study did
Phase 2 (73)
HR+/HER2- Metastatic Breast Cancer
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT02538432 · University of Maryland, Baltimore
2017-06 – 2021-12 · Prostate Cancer, Non-Small Cell Lung Cancer, Breast Cancer
What this study did
NCT03887130 · Pierre Fabre Medicament
2007-03-27 – 2013-04-18 · Breast Cancer
What this study did
NCT00325234 · Eli Lilly and Company
2006-06 – 2010-08 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT07420439 · Intergroupe Francophone de Cancerologie Thoracique
2026-09-15 – 2028-11-15 · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03971474 · SWOG Cancer Research Network
2019-05-28 – 2024-01-01 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02489903 · EpicentRx, Inc.
2015-06 – 2021-12-06 · Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
What this study did
NCT02117024 · Heat Biologics
2014-07 – 2018-04 · Non Small Cell Lung Cancer
What this study did
NCT01395758 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2011-07 – 2016-08 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT00754364 · Armando Santoro, MD
2008-10 – 2015-12 · NSCLC
What this study did
NCT01810367 · Fudan University
2011-12 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT01236716 · Chinese Society of Lung Cancer
2010-11 – 2014-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00600587 · Guangdong Provincial People's Hospital
2007-09 – 2013-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00193921 · Trans Tasman Radiation Oncology Group
2003-02 – 2012-12 · Non Small Cell Lung Carcinoma
What this study did
NCT00173888 · National Taiwan University Hospital
2003-07 – 2012-11 · Non-small Cell Lung Cancer
What this study did
NCT01194453 · Sun Yat-sen University
2009-11 – 2012-08 · Non-small Cell Lung Cancer, Efficacy
What this study did
NCT00536640 · Aktion Bronchialkarzinom e.V.
2007-11 – 2012-05 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00264498 · AstraZeneca
2004-10 – 2008-06 · Carcinoma, Non-Small-Cell Lung
What this study did
Ovarian Cancer
NCT07776171 · Sun Yat-sen University
2026-09-30 – 2030-05-30 · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)
What this study did
NCT07504588 · National Cancer Institute (NCI)
2026-09-24 – 2029-04-12 · Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
What this study did
NCT04274426 · AGO Research GmbH
2021-10-13 – 2026-12 · Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
What this study did
NCT03783949 · Universitaire Ziekenhuizen KU Leuven
2018-11-30 – 2023-09-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT02822157 · Universitaire Ziekenhuizen KU Leuven
2016-08 – 2023-07 · Ovarian Epithelial Cancer
What this study did
NCT01121406 · Boehringer Ingelheim
2010-04 – 2014-06 · Ovarian Neoplasms
What this study did
Pancreatic Cancer
NCT04571489 · Lee's Pharmaceutical Limited
2020-12-01 – 2023-12-01 · Pancreatic Cancer
What this study did
NCT03487016 · Ludwig-Maximilians - University of Munich
2019-02-15 – 2023-07 · Metastatic Pancreatic Cancer
What this study did
NCT03563144 · ImmunityBio, Inc.
2018-08 – 2022-02-09 · Metastatic Pancreatic Cancer
What this study did
NCT03636308 · Peking University
2018-07-17 – 2021-08-01 · Pancreatic Cancer
What this study did
NCT02704156 · Changhai Hospital
2016-10 – 2020-12 · Pancreatic Cancer
What this study did
NCT01867892 · National Health Research Institutes, Taiwan
2013-06 – 2019-05 · Pancreatic Cancer
What this study did
NCT01964534 · GERCOR - Multidisciplinary Oncology Cooperative Group
2013-12-12 – 2017-07 · Metastatic Pancreatic Cancer
What this study did
NCT01509911 · Tiltan Pharma Ltd.
2012-01 – 2017-01 · Metastatic Pancreatic Cancer
What this study did
NCT01303172 · Immodulon Therapeutics Ltd
2011-06 – 2016-01 · Advanced Pancreatic Cancer
What this study did
NCT00499265 · Heidelberg Pharma AG
2007-04 – 2010-05 · Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT05047991 · CSPC Ouyi Pharmaceutical Co., Ltd.
2021-10 – 2024-11 · Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
What this study did
NCT03974854 · Centre Hospitalier Universitaire de Besancon
2019-07-08 – 2024-02-01 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT01124786 · Clovis Oncology, Inc.
2010-05 – 2013-06 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT00558207 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2007-11 – 2008-04 · Pancreatic Neoplasms
What this study did
Other / comorbidity
NCT06770582 · National Cancer Institute (NCI)
2025-06-03 – 2032-02-01 · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
What this study did
NCT07797881 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2030-12 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT04747236 · University of Virginia
2021-02-19 – 2030-06-02 · PTCL
What this study did
NCT03547973 · Gilead Sciences
2018-08-13 – 2030-04 · Metastatic Urothelial Cancer
What this study did
NCT06023862 · Yonsei University
2024-01-22 – 2029-12-31 · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell Carcinoma
What this study did
NCT07647289 · Peking University Third Hospital
2025-04-15 – 2028-12 · Muscle-Invasive Bladder Cancer (MIBC)
What this study did
NCT07654530 · Tianjin Medical University Cancer Institute and Hospital
2026-04-24 – 2028-06-30 · Biliary Tract Cancers (BTC)
What this study did
Phase 1/2 (4)
Non-Small Cell Lung Cancer
NCT02574078 · Bristol-Myers Squibb
2015-11-23 – 2020-04-15 · Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06843447 · Merck Sharp & Dohme LLC
2025-04-15 – 2031-02-07 · Ovarian Cancer Recurrent
What this study did
Pancreatic Ductal Adenocarcinoma
NCT05218889 · Chinese PLA General Hospital
2021-08-04 – 2025-06 · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
What this study did
Other / comorbidity
NCT03607643 · Leaf Vertical Inc.
2019-01-15 – 2020-12-15 · Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
What this study did
Phase 1 (1)
Other / comorbidity
NCT01803152 · Macarena De La Fuente, MD
2014-01-06 – 2024-06-21 · Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT02996214 · Nanjing Luye Sike Pharmaceutical Co., Ltd.
2016-11 – 2020-06 · Squamous Non-small-cell Lung Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07389356 · The First Affiliated Hospital with Nanjing Medical University
2026-02-25 – 2029-12-30 · DLBCL - Diffuse Large B Cell Lymphoma
What this study did
Studied as part of a combination product (5)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (2)
Pancreatic Cancer
NCT03257033 · RenovoRx
2018-03-12 – 2027-09 · Locally Advanced Pancreatic Cancer
What this study did
Other / comorbidity
NCT07464145 · Relmada Therapeutics, Inc.
2027-02 – 2032-12 · Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer
What this study did
Phase 2 (1)
Other / comorbidity
NCT06663137 · Relmada Therapeutics, Inc.
2024-08-01 – 2027-12 · Non Muscle Invasive Bladder Cancer
What this study did
Phase 1/2 (1)
Pancreatic Ductal Adenocarcinoma
NCT07477418 · University of Vermont
2026-12 – 2031-12 · Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
What this study did
Phase 1 (1)
Pancreatic Ductal Adenocarcinoma
NCT07481383 · Continuity Biosciences, LLC
2026-03-11 – 2027-11-01 · Pancreatic Adenocarcinoma Non-resectable
What this study did
Appears in other studies (450)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (97)
HR+/HER2- Metastatic Breast Cancer
NCT07088263 · Sun Yat-sen University
2025-09-15 – 2028-06-24 · Breast Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT06623422 · Merck Sharp & Dohme LLC
2024-10-21 – 2038-01-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07050043 · Dr Arvindran A/L Alaga
2025-05-19 – 2030-12-31 · NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC
What this study did
NCT06632327 · Alliance for Clinical Trials in Oncology
2024-12-11 – 2030-04-30 · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT04267848 · National Cancer Institute (NCI)
2020-06-16 – 2030-01-31 · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT03800134 · AstraZeneca
2018-12-06 – 2028-09-11 · Non-Small Cell Lung Cancer
What this study did
NCT01405586 · National Cancer Institute, Naples
2011-03 – 2024-11 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT03629925 · Innovent Biologics (Suzhou) Co. Ltd.
2018-09-28 – 2021-09-30 · Squamous NSCLC
What this study did
NCT01041781 · Alliance for Clinical Trials in Oncology
2010-02 – 2018-03 · Lung Cancer
What this study did
NCT02900742 · Shanghai University of Traditional Chinese Medicine
2013-03 – 2017-06-01 · Cancer
What this study did
NCT02001896 · Xinjiang Medical University
2013-12 – 2015-06 · Non-Small Cell Lung Cancer
What this study did
NCT00883779 · Hoffmann-La Roche
2009-04 – 2014-12 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT00526643 · National Cancer Institute, Naples
2007-11 – 2012-12 · Non-Small Cell Lung Cancer
What this study did
NCT00806923 · Hoffmann-La Roche
2005-02 – 2011-02 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT00003159 · Medical Research Council
1997-08 – 2007-06 · Lung Cancer
What this study did
Ovarian Cancer
NCT05281471 · Genelux Corporation
2022-08-31 – 2027-12 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
What this study did
NCT03598270 · Grupo Español de Investigación en Cáncer de Ovario
2018-11-21 – 2024-08-05 · Recurrent Ovarian Carcinoma
What this study did
NCT00434642 · Genentech, Inc.
2007-04 – 2013-07 · Ovarian Cancer
What this study did
Pancreatic Cancer
NCT07383922 · FutureGen Biopharmaceutical (Beijing) Co., Ltd
2026-02-28 – 2030-12-31 · Pancreatic Cancer
What this study did
NCT07079228 · Qilu Pharmaceutical Co., Ltd.
2025-09-08 – 2030-09 · Pancreatic Cancer
What this study did
NCT07436741 · Tianjin Medical University Cancer Institute and Hospital
2026-03-03 – 2030-03 · Pancreatic Cancer, Adult
What this study did
NCT07272109 · Fudan University
2026-01-01 – 2028-12-30 · Pancreatic Cancer
What this study did
NCT06953999 · Akeso
2025-06-11 – 2028-05-14 · Pancreatic Cancer
What this study did
NCT06752811 · Shanghai Yizhong Pharmaceutical Co., Ltd.
2025-02-05 – 2027-12-31 · Pancreatic Cancer Metastatic
What this study did
NCT05653453 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
2022-12-20 – 2027-09-28 · Locally Advanced Pancreatic Cancer
What this study did
NCT06017284 · Fudan University
2023-11-01 – 2026-11-30 · Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
What this study did
NCT01964430 · Celgene
2014-03-28 – 2022-06-30 · Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
What this study did
NCT02395016 · Biotech Pharmaceutical Co., Ltd.
2015-04 – 2021-11 · Pancreatic Cancer
What this study did
NCT03766295 · AB Science
2014-07 – 2020-12 · Locally Advanced or Metastatic Pancreatic Cancer
What this study did
NCT02043288 · Orient Europharma Co., Ltd.
2014-01 – 2019-12 · Pancreatic Neoplasms
What this study did
NCT01231347 · NantCell, Inc.
2011-04-07 – 2012-12-12 · Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer, Bone Metastases, Endocrine Cancer, Oncology, Oncology Patients, Solid Tumors, Advanced Malignancy
What this study did
NCT00789633 · AB Science
2008-11-25 – 2012-08-31 · Pancreatic Cancer
What this study did
NCT00813696 · Istituti Tumori Giovanni Paolo II
2002-04 – 2009-09 · Pancreatic Cancer
What this study did
NCT00088894 · National Cancer Institute (NCI)
2004-06 – 2006-06 · Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06998940 · SWOG Cancer Research Network
2026-05-13 – 2030-12 · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT06608927 · Arcus Biosciences, Inc.
2024-12-13 – 2030-11-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07621718 · Revolution Medicines, Inc.
2026-05-22 – 2030-04-22 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
NCT07491445 · Revolution Medicines, Inc.
2026-03-09 – 2029-03 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
NCT07165951 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
2025-12-02 – 2028-12 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07445295 · Chipscreen Biosciences, Ltd.
2026-03-31 – 2028-11-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT04969731 · GC Cell Corporation
2021-09-07 – 2027-06 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT04935359 · Novartis Pharmaceuticals
2021-09-30 – 2024-08-13 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT03943667 · UNICANCER
2019-05-23 – 2022-04-26 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT03126435 · SynCore Biotechnology Co., Ltd.
2018-10-16 – 2021-10-08 · Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
What this study did
NCT02101021 · Sierra Oncology LLC - a GSK company
2014-06-02 – 2017-04-10 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
Phase 2/3 (16)
Ovarian Cancer
NCT02490488 · AB Science
2014-04 – 2020-12 · Ovarian Cancer
What this study did
Pancreatic Cancer
NCT06361888 · Hutchmed
2024-05-08 – 2028-05-31 · Metastatic Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT05254171 · Panbela Therapeutics, Inc.
2022-08-08 – 2027-01-01 · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
What this study did
Other / comorbidity
NCT07544056 · BeBetter Med Inc
2026-06-04 – 2030-12 · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
What this study did
NCT07765433 · ECOG-ACRIN Cancer Research Group
2027-01-11 – 2029-12-31 · Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma, Metastatic Biliary Tract Adenocarcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Adenocarcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT06214572 · Tata Memorial Centre
2024-03-07 – 2029-07-21 · Gall Bladder Cancer
What this study did
NCT07366840 · Fudan University
2026-01-16 – 2029-01-16 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07598318 · Sir Run Run Shaw Hospital
2026-05-20 – 2028-12-31 · Cholangiocarcinoma
What this study did
NCT06719479 · SUNHO(China)BioPharmaceutical CO., Ltd.
2025-01-01 – 2028-01-01 · NPC, HNSCC, Recurrence, Metastasis
What this study did
NCT04628767 · National Cancer Institute (NCI)
2021-11-12 – 2027-09-30 · Renal Pelvis and Ureter Urothelial Carcinoma
What this study did
NCT05139017 · Merck Sharp & Dohme LLC
2022-01-14 – 2027-09-24 · DLBCL, Diffuse Large B-Cell Lymphoma
What this study did
NCT04442022 · Karyopharm Therapeutics Inc
2020-09-03 – 2026-12 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT04066491 · EMD Serono Research & Development Institute, Inc.
2019-09-20 – 2022-11-10 · Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
What this study did
NCT00939848 · University College, London
2011-04 – 2014-09 · Biliary Tract Neoplasms
What this study did
NCT00389155 · Bristol-Myers Squibb
2007-01 – 2008-01 · Bladder Cancer, Transitional Cell Carcinoma, Metastasis
What this study did
Phase 2 (201)
HR+/HER2- Metastatic Breast Cancer
NCT06449222 · BioNTech SE
2024-08-26 – 2029-06 · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
What this study did
NCT05601440 · Canadian Cancer Trials Group
2023-06-13 – 2028-06-30 · Breast Cancer
What this study did
NCT06533722 · Sun Yat-sen University
2024-08-04 – 2025-05-28 · HER2-negative Metastatic Breast Cancer
What this study did
NCT00323063 · Rutgers, The State University of New Jersey
2006-05-01 – 2016-06-20 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06788912 · Merck Sharp & Dohme LLC
2025-03-20 – 2032-02-06 · Lung Neoplasm Malignant
What this study did
NCT05733000 · Northwestern University
2023-03-08 – 2030-03-04 · Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04892953 · M.D. Anderson Cancer Center
2021-07-07 – 2029-09-30 · Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
What this study did
NCT07158489 · Swiss Cancer Institute
2026-08-21 – 2029-07-31 · NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT03137771 · NRG Oncology
2017-04-07 – 2028-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT04846634 · Tianjin Medical University Cancer Institute and Hospital
2021-08 – 2028-02 · Resectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT04470076 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-07-10 – 2023-07-30 · Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy, EGFR TKI
What this study did
NCT04586465 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-10-10 – 2022-06-30 · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, PET/CT
What this study did
NCT02940990 · Shanghai Chest Hospital
2016-11 – 2019-12 · NSCLC, SBRT, GM-CSF
What this study did
NCT02930954 · Caicun Zhou
2016-11 – 2018-12 · Non-small-cell Lung Cancer
What this study did
NCT02276560 · UNC Lineberger Comprehensive Cancer Center
2015-01 – 2016-06 · Stage IIIA Non-Small Cell Lung Cancer
What this study did
NCT01784549 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2012-07 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT01998919 · Hoffmann-La Roche
2006-08 – 2011-11 · Non-Small Cell Lung Cancer
What this study did
NCT00413283 · Amgen
2006-12 – 2009-02 · Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
What this study did
NCT00518011 · Hoffmann-La Roche
2007-08 – 2009-02 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT03983226 · Shanghai Gynecologic Oncology Group
2019-10-18 – 2026-12 · Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05979298 · CureLab Oncology
2019-11-15 – 2023-12-30 · Ovarian Cancer, Platinum-resistant Ovarian Cancer
What this study did
NCT01610206 · Linda R Duska
2012-09 – 2020-12-31 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT01696032 · Astex Pharmaceuticals, Inc.
2012-09 – 2016-08 · Ovarian Cancer
What this study did
Pancreatic Cancer
NCT07283705 · M.D. Anderson Cancer Center
2026-04-09 – 2031-10-01 · Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer
What this study did
NCT04589234 · Salspera LLC
2020-10-20 – 2030-12-31 · Metastatic Pancreatic Cancer
What this study did
NCT07828756 · Tianjin Medical University Cancer Institute and Hospital
2026-09-30 – 2030-04-30 · Pancreatic Cancer
What this study did
NCT07833241 · Shanghai Zhongshan Hospital
2026-09-01 – 2029-09-01 · Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer
What this study did
NCT05776524 · THERABIONIC INC.
2023-06-13 – 2029-07 · Pancreatic Cancer, Metastatic Adenocarcinoma
What this study did
NCT04241276 · Queen Mary University of London
2020-04-30 – 2029-02-28 · Pancreatic Cancer
What this study did
NCT07578337 · Nelum Corp
2026-07-15 – 2029-02-28 · Untreated, Advanced Pancreatic Cancer
What this study did
NCT06177522 · Jinling Hospital, China
2025-11-30 – 2028-12-31 · Pancreatic Cancer, Neoadjuvant Therapy
What this study did
NCT07806110 · The First Hospital of Jilin University
2026-07-30 – 2028-12-31 · Pancreas Ductal Adenocarcinoma
What this study did
NCT07864571 · Jun Gong, MD
2026-12 – 2028-12 · Pancreatic Cancer
What this study did
NCT05562297 · Shanghai Zhongshan Hospital
2025-03-20 – 2028-10-01 · Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage III
What this study did
NCT07871461 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
2026-10 – 2028-09 · Pancreatic Cancer
What this study did
NCT06770452 · Zhejiang University
2025-03-25 – 2028-02-01 · Metastatic Pancreatic Carcinoma
What this study did
NCT06770439 · Zhejiang University
2025-04-18 – 2028-01 · Advanced Pancreatic Cancers
What this study did
NCT06951997 · Tianjin Medical University Cancer Institute and Hospital
2025-03-07 – 2027-12-31 · Metastatic Pancreatic Cancer
What this study did
NCT05827055 · Georgetown University
2024-01-31 – 2027-01 · Metastatic Pancreatic Cancer
What this study did
NCT06234072 · Shenzhen University General Hospital
2024-02 – 2027-01 · Pancreatic Cancer
What this study did
NCT05969171 · Fudan University
2023-12-05 – 2026-12-31 · Pancreatic Cancer Metastatic
What this study did
NCT02340117 · SynerGene Therapeutics, Inc.
2015-01 – 2026-12 · Metastatic Pancreatic Cancer
What this study did
NCT04089150 · Australasian Gastro-Intestinal Trials Group
2019-10-01 – 2023-08-30 · Pancreatic Cancer
What this study did
NCT02635971 · Fudan University
2015-12 – 2022-12 · Carcinoma, Pancreatic
What this study did
NCT02106884 · Universitaire Ziekenhuizen KU Leuven
2014-04 – 2019-04-29 · Pancreatic Cancer
What this study did
NCT01150630 · IRCCS San Raffaele
2010-05 – 2017-08 · Pancreatic Cancer
What this study did
NCT01210911 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2010-08 – 2014-04 · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
What this study did
Phase 1/2 (74)
HR+/HER2- Metastatic Breast Cancer
NCT05981001 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-04-30 · Breast Neoplasms
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT06026657 · Margaret Gatti-Mays
2024-04-02 – 2027-10-31 · Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
What this study did
NCT06202261 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-04-13 – 2027-10 · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
What this study did
Non-Small Cell Lung Cancer
NCT04198766 · Inhibrx Biosciences, Inc
2019-12-10 – 2033-07 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT07563738 · Orion Corporation, Orion Pharma
2026-03-27 – 2029-09 · Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
Ovarian Cancer
NCT01663857 · Eli Lilly and Company
2012-07 – 2018-05-11 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Pancreatic Cancer
NCT07802184 · West China Hospital
2026-09-21 – 2029-05-01 · Metastatic Pancreatic Cancer
What this study did
NCT06888674 · Zhejiang University
2025-04-01 – 2029-04-01 · Pancreatic Cancer Resectable
What this study did
NCT07280377 · Oncolytics Biotech
2021-10-27 – 2028-12-31 · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
What this study did
NCT06030622 · State University of New York - Downstate Medical Center
2024-04-17 – 2028-12-30 · Pancreatic Cancer Metastatic
What this study did
NCT06821503 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-04-11 – 2028-12 · Advanced Pancreatic Cancer
What this study did
NCT07444541 · Anova Innovation Limited
2026-12 – 2028-12 · Pancreatic Cancer
What this study did
NCT06662669 · Shanghai YingLi Pharmaceutical Co. Ltd.
2024-11-30 – 2028-08-30 · Metastatic Pancreatic Cancer
What this study did
NCT07575191 · Smartwise Sweden AB
2026-04-29 – 2028-06 · Pancreatic Cancer Non-resectable
What this study did
NCT06513455 · Harbin Medical University
2024-09-01 – 2027-12-31 · Pancreatic Cancer
What this study did
NCT07701486 · Theriva Biologics SL
2026-07-31 – 2027-12-01 · Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas
What this study did
NCT07296341 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-01-08 – 2027-12 · Locally Advanced or Metastatic Pancreatic Cancer With
What this study did
NCT04396821 · Transcenta Therapeutics (Hangzhou) Co., Ltd.
2020-05-28 – 2027-09-30 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
What this study did
NCT07777211 · Beijing Gene Key Life Technology Co., Ltd
2025-08-14 – 2027-08-31 · Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas
What this study did
NCT03579836 · BeyondBio Inc.
2018-05-14 – 2026-12-31 · Locally Advanced or Metastatic Pancreatic Cancer
What this study did
NCT03652428 · University of Maryland, Baltimore
2019-04-02 – 2026-12-31 · Locally Advanced Pancreatic Cancer
What this study did
NCT03086369 · Eli Lilly and Company
2017-06-22 – 2021-06-17 · Metastatic Pancreatic Cancer
What this study did
NCT00907166 · Cornerstone Pharmaceuticals
2009-05 – 2017-12 · Cancer, Pancreatic Cancer, Pancreatic Carcinoma
What this study did
NCT01453153 · Halozyme Therapeutics
2011-09 – 2015-05 · Stage IV Pancreatic Cancer
What this study did
NCT00839332 · Eli Lilly and Company
2009-02 – 2013-12 · Pancreatic Neoplasms
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06592664 · Lisata Therapeutics, Inc.
2030-01 – 2040-01 · Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT07640295 · Jacobio Pharmaceuticals Co., Ltd.
2026-07-16 – 2030-12-31 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07665684 · University Health Network, Toronto
2026-07 – 2030-05 · Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous Carcinoma of the Pancreas, Mucinous Adenocarcinoma
What this study did
NCT05257993 · Onconic Therapeutics Inc.
2022-03-30 – 2030-04 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT06445062 · Revolution Medicines, Inc.
2024-05-24 – 2030-03-30 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06904378 · Washington University School of Medicine
2026-03-25 – 2029-09-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07685470 · Peking Union Medical College Hospital
2026-06-08 – 2029-06-07 · Pancreatic Ductal Adenocarcinoma (PDAC), Second Line Treatment
What this study did
NCT07235202 · Shenzhen Majory Biotechnology Co., Ltd.
2025-12-24 – 2028-12-22 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT07020221 · Verastem, Inc.
2025-06-24 – 2028-12 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
What this study did
NCT07475234 · Xiuchao Wang
2026-03 – 2028-12 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07223047 · Bristol-Myers Squibb
2025-11-25 – 2028-10-13 · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT07049055 · Engeneic Pty Limited
2026-01-12 – 2028-09 · Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT07678593 · Genfleet Therapeutics (Shanghai) Inc.
2026-09 – 2028-09 · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
What this study did
NCT05431270 · Phanes Therapeutics
2022-08-11 – 2028-08 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT04657068 · Artios Pharma Ltd
2021-01-27 – 2028-06 · Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
What this study did
NCT05482893 · Phanes Therapeutics
2023-03-15 – 2028-04 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
What this study did
NCT07705919 · Ohio State University Comprehensive Cancer Center
2026-10-01 – 2027-12-31 · Borderline Resectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT06646055 · Akeso
2025-01-21 – 2027-12-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06922591 · Tango Therapeutics, Inc.
2025-05-31 – 2027-12 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
What this study did
NCT06483555 · UNC Lineberger Comprehensive Cancer Center
2025-02-06 – 2027-08 · Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
What this study did
NCT06345599 · Second Affiliated Hospital of Soochow University
2024-05-01 – 2027-01-10 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT00201838 · Ohio State University Comprehensive Cancer Center
2001-07 – 2007-05 · Pancreatic Neoplasms, Adenocarcinoma
What this study did
Other / comorbidity
NCT07850973 · M.D. Anderson Cancer Center
2027-03-01 – 2031-12-31 · Germ Cell Cancer
What this study did
Phase 1 (45)
HR+/HER2- Metastatic Breast Cancer
NCT06840886 · Pheast Therapeutics
2025-03-31 – 2031-04 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
What this study did
Non-Small Cell Lung Cancer
NCT05919537 · Hummingbird Bioscience
2023-09-06 – 2031-03-01 · Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT04491942 · National Cancer Institute (NCI)
2021-08-25 – 2027-06-30 · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT00599755 · Merck Sharp & Dohme LLC
2009-01-01 – 2011-04-13 · Carcinoma, Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT04516447 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
2020-10-26 – 2028-06-30 · Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT03854110 · Persevere Therapeutics Inc.
2019-01-14 – 2027-09-30 · Ovarian Cancer
What this study did
NCT01970722 · City of Hope Medical Center
2014-07-01 – 2027-01-05 · FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
What this study did
Pancreatic Cancer
NCT06532331 · Ono Pharmaceutical Co., Ltd.
2023-12-06 – 2028-03-31 · Metastatic Pancreatic Cancer
What this study did
NCT05497778 · M.D. Anderson Cancer Center
2022-10-21 – 2027-02-02 · Pancreas Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06607185 · Eli Lilly and Company
2024-10-21 – 2030-01 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT07699757 · Haisco Pharmaceutical Group Co., Ltd.
2026-07 – 2029-11 · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
What this study did
NCT06917079 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2025-03-31 – 2029-09 · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
What this study did
NCT07458347 · Kestrel Therapeutics, Inc.
2026-04-21 – 2029-04 · KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
What this study did
NCT07377045 · Oncomatryx Biopharma S.L.
2025-10-28 – 2029-03 · Pancreatic Adenocarcinoma Metastatic
What this study did
NCT06639724 · University of California, San Diego
2024-12-05 – 2028-12 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT06182072 · ProDa BioTech, LLC
2023-09-14 – 2028-06-30 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT07619313 · Jonsson Comprehensive Cancer Center
2026-05-29 – 2028-06-01 · Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT06586515 · Eli Lilly and Company
2024-09-12 – 2028-03 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT06393400 · John Lenehan
2025-01-08 – 2028-02 · Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
What this study did
NCT07024615 · Astellas Pharma Global Development, Inc.
2025-10-16 – 2028-01-31 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT04999761 · Taiho Pharmaceutical Co., Ltd.
2021-06-01 – 2027-06 · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
What this study did
NCT06454383 · City of Hope Medical Center
2024-06-10 – 2027-03-23 · Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT07348107 · Daniel Breadner
2026-02-15 – 2027-03 · Advanced Pancreatic Ductal Adenocarcinoma
What this study did
NCT03816358 · National Cancer Institute (NCI)
2019-12-09 – 2027-01-31 · Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
Other / comorbidity
NCT07107750 · Washington University School of Medicine
2026-03-27 – 2032-05-31 · Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
What this study did
NCT06308419 · M.D. Anderson Cancer Center
2024-08-14 – 2031-02-01 · Leiomyosarcoma, Soft-tissue Sarcomas
What this study did
NCT07308132 · Janssen Research & Development, LLC
2026-01-20 – 2029-10-31 · Lymphoma, Non-Hodgkin
What this study did
NCT07821177 · Dana-Farber Cancer Institute
2026-09-02 – 2029-09 · Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
What this study did
NCT07353294 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-01-01 – 2029-06-30 · Bladder Urothelial Carcinoma, Lymph Node Metastasis
What this study did
NCT07532902 · Memorial Sloan Kettering Cancer Center
2026-04-07 – 2029-04 · Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
What this study did
NCT06181032 · First Affiliated Hospital of Fujian Medical University
2023-12-23 – 2029-02-23 · Biliary Tract Malignancies
What this study did
NCT05382559 · Astellas Pharma Inc
2022-06-08 – 2028-12-31 · Solid Tumor
What this study did
NCT06546969 · University of Maryland, Baltimore
2024-10-29 – 2028-12 · Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT05285358 · City of Hope Medical Center
2022-09-19 – 2028-10-11 · Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
What this study did
NCT06447376 · Taylor Brooks
2025-01-14 – 2028-09-01 · Non-Hodgkin Lymphoma, Cytokine Release Syndrome
What this study did
NCT06204614 · Brigham and Women's Hospital
2024-06-14 – 2028-08-01 · Muscle Invasive Bladder Urothelial Carcinoma
What this study did
NCT07144254 · Emory University
2026-01-22 – 2028-05 · Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
What this study did
NCT03233139 · Regeneron Pharmaceuticals
2017-06-21 – 2027-09-30 · Advanced Malignancies
What this study did
NCT03321643 · National Cancer Institute (NCI)
2018-09-18 – 2027-06-30 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05101551 · Norman J. Lacayo
2023-02-23 – 2027-04 · Acute Myeloid Leukemia
What this study did
NCT06624085 · Hoffmann-La Roche
2025-04-28 – 2027-03-22 · Lymphoma
What this study did
NCT04161248 · Canadian Cancer Trials Group
2020-09-02 – 2026-12-31 · Lymphoma, B-Cell
What this study did
NCT03628521 · Shanghai Chest Hospital
2018-07-20 – 2020-12-31 · Lung Cancer, Advanced Stage
What this study did
NCT00220649 · St. Luke's-Roosevelt Hospital Center
started 2004-03 · Pancreatic Neoplasms
What this study did
Phase 4 (6)
Pancreatic Cancer
NCT07302841 · Tianjin Medical University Cancer Institute and Hospital
2026-01-20 – 2028-12-30 · Pancreatic Cancer Non-resectable
What this study did
Other / comorbidity
NCT07801027 · Merck Sharp & Dohme LLC
2026-11-06 – 2030-01-31 · Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical Neoplasms
What this study did
NCT06818773 · Eastern Hepatobiliary Surgery Hospital
2025-02 – 2027-12-31 · Metastatic Biliary Tract Cancer, HER2 Positive
What this study did
NCT06457503 · Coherus Oncology, Inc.
2024-11-01 – 2027-12 · Nasopharyngeal Cancer Recurrent
What this study did
Early phase / not applicable (11)
Ovarian Cancer
NCT06292286 · The University of Hong Kong
2023-11-01 – 2026-12-31 · Recurrent Ovarian Carcinoma
What this study did
Pancreatic Cancer
NCT04894643 · EBG MedAustron GmbH
2020-09-14 – 2027-12-31 · Pancreatic Cancer, Proton Therapy
What this study did
NCT03690323 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2015-04-07 – 2020-05 · Locally Advanced Pancreatic Cancer
What this study did
NCT02685228 · The First Hospital of Jilin University
2016-03 – 2018-12 · Pancreatic Cancer
What this study did
Pancreatic Ductal Adenocarcinoma
NCT02921022 · Memorial Sloan Kettering Cancer Center
2016-10 – 2027-10 · Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
What this study did
Other / comorbidity
NCT06434493 · The Christie NHS Foundation Trust
2025-10-03 – 2029-11-01 · Cholangiocarcinoma
What this study did
NCT07466238 · Peking University
2026-03-31 – 2029-03-31 · Biliary Tract Cancer (BTC)
What this study did
NCT07853690 · NYU Langone Health
2026-10-05 – 2028-09 · Biliary Track Cancer
What this study did
NCT05352321 · Sun Yat-sen University
2022-06-01 – 2028-06-01 · Nasopharyngeal Carcinoma
What this study did
NCT06611345 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
2024-10-21 – 2027-03-30 · Biliary Tract Cancers (BTC)
What this study did
NCT02627807 · Sun Yat-sen University
2015-12 – 2022-12 · Nasopharyngeal Neoplasms
What this study did

Competitive landscape

Other ribonucleotide reductase / DNA polymerase (dCTP competition) drugs

Gemcitabine (FF-10832). Compare all 2 ribonucleotide reductase / DNA polymerase (dCTP competition) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gemcitabine: this drugApprovedSmall moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
Daraxonrasib (Rasonque)Phase 3Small moleculepan-RAS, RAS (pan-RAS, RAS-mutant tumors)not yet gradedNo reviewed efficacy summary in this indication
GFH375Phase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
INCB161734
Phase 3(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
SetidegrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
ZoldonrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
NavlimetostatPhase 2/3Small moleculePRMT5 (protein arginine methyltransferase 5), MTA-cooperative bindingnot yet gradedNo reviewed efficacy summary in this indication
AtebimetinibPhase 2Small moleculeMEK (MAP2K1/2)not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
ERAS-0015Phase 2Small moleculepan-RASnot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine (FF-10832)Phase 2Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Nuzefatide PevedotinPhase 1/2PeptideEphA2not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
VopimetostatPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 102 furthest-along competitors are listed; 508 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(82 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gemcitabine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
November 2026 (1)
Phase 3Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT06156514 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT02889666 · CT.gov ↗
What to watch
Phase 3Hepatoblastoma, Carcinoma, HepatocellularActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT03017326 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04115163 · CT.gov ↗
What to watch
Phase 2Bladder Cancer, Non-muscle InvasiveActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05024734 · CT.gov ↗
What to watch
Phase 3Cervical Cancer, Cervix Cancer, Cervix NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05764044 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, RadiotherapyActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05975307 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07014943 · CT.gov ↗
What to watch
2027 (30)
February 2027 (1)
Phase 2Pancreatic Ductal AdenocarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02-28 · NCT06492915 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Olfactory NeuroblastomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-01 · NCT06255210 · CT.gov ↗
What to watch
Phase 3Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT03533582 · CT.gov ↗
What to watch
April 2027 (1)
Early phase / not applicablePancreatic CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT06494514 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Pancreatic CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT05451043 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1/2Non-Small Cell Lung CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT05585320 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT05825066 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-20 · NCT07163273 · CT.gov ↗
What to watch
Phase 3Recurrent Nasopharyngeal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06235203 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1/2NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma BladderNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT07064863 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Bladder CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08 · NCT06488222 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial CarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-15 · NCT07492225 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-31 · NCT06423326 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Urinary Bladder CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT07184021 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Pancreatic CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT03492671 · CT.gov ↗
What to watch
Phase 2Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07189793 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2Non-Muscle Invasive Bladder Cancer (NMIBC)Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT04179162 · CT.gov ↗
What to watch
Phase 2Bladder (Urothelial, Transitional Cell) CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT07019220 · CT.gov ↗
What to watch
Phase 1Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT03093909 · CT.gov ↗
What to watch
December 2027 (11)
Phase 3Bladder Cancer, Bladder Urothelial CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT04574960 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12 · NCT05026905 · CT.gov ↗
What to watch
Phase 2/3Pancreatic Ductal AdenocarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT06115499 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT04683315 · CT.gov ↗
What to watch
Phase 1Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06229496 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06388720 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, ImmunotherapyNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06567600 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Pancreatic Cystic NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07529483 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07897565 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07928362 · CT.gov ↗
What to watch
2028 (20)
January 2028 (1)
Early phase / not applicableUTUCRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-30 · NCT06167057 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT06822010 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05 · NCT07076212 · CT.gov ↗
What to watch
Phase 2/3Non Muscle Invasive Bladder CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05 · NCT07198451 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05 · NCT07418931 · CT.gov ↗
What to watch
June 2028 (3)
Phase 3Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-05 · NCT07000084 · CT.gov ↗
What to watch
Phase 3Recurrent Nasopharyngeal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT06228079 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT07945782 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2/3Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8 …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT04559139 · CT.gov ↗
What to watch
Phase 2Pancreas AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT07043270 · CT.gov ↗
What to watch
Phase 3MIBCRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07-01 · NCT07693959 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-01 · NCT05800587 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09 · NCT07020065 · CT.gov ↗
What to watch
Phase 2LeiomyosarcomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-30 · NCT04535271 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-01 · NCT07883135 · CT.gov ↗
What to watch
Phase 2MedulloblastomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10-13 · NCT01878617 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2/3Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable, Borderline ResectableRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-06 · NCT06923475 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2/3Biliary Tract Cancer, CholangiocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT06037980 · CT.gov ↗
What to watch
Phase 2PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07888621 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07902713 · CT.gov ↗
What to watch
2029 (11)
January 2029 (3)
Phase 1Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01 · NCT07875907 · CT.gov ↗
What to watch
Phase 3Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-01 · NCT06897644 · CT.gov ↗
What to watch
Phase 2/3EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7 …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-31 · NCT02135042 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Locally Advanced / Metastatic Solid TumorsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02 · NCT07335497 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-04 · NCT07616362 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Solid Tumor CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06 · NCT07671534 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09 · NCT04796220 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-10-01 · NCT07908979 · CT.gov ↗
What to watch
November 2029 (2)
Early phase / not applicablePancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-11 · NCT06046794 · CT.gov ↗
What to watch
Phase 3Non-muscle-invasive Bladder CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-11-01 · NCT05538663 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-30 · NCT07747740 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 2Urothelial CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-01-01 · NCT07043972 · CT.gov ↗
What to watch
February 2030 (1)
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-02-03 · NCT07748611 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Pancreatic CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-31 · NCT07155629 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09-30 · NCT07096362 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low GradeNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-11-30 · NCT06227065 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-11-30 · NCT07900789 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Nasopharyngeal Cancinoma (NPC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-31 · NCT07904819 · CT.gov ↗
What to watch
2031 (2)
June 2031 (1)
Phase 2/3Pancreatic CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-06-02 · NCT06783140 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Malignant Neoplasms of Digestive OrgansRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-12-31 · NCT06714604 · CT.gov ↗
What to watch
2033 (1)
January 2033 (1)
Phase 2Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS) …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2033-01-01 · NCT07322263 · CT.gov ↗
What to watch
2034 (1)
June 2034 (1)
Phase 2Triple Negative Breast Cancer, Metastatic Triple-negative Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2034-06-01 · NCT07528768 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗